American National Bank raised its position in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 142,997 shares of the biopharmaceutical company’s stock after buying an additional 3,048 shares during the period. Pfizer comprises about 1.8% of American National Bank’s portfolio, making the stock its 17th largest position. American National Bank’s holdings in Pfizer were worth $4,616,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Lowe FS boosted its stake in shares of Pfizer by 54.9% in the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock worth $23,000 after buying an additional 260 shares during the last quarter. Taylor Wealth Management Partners boosted its stake in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 105 shares during the last quarter. Simplex Trading boosted its stake in shares of Pfizer by 94.3% in the fourth quarter. Simplex Trading now owns 4,986 shares of the biopharmaceutical company’s stock worth $903,000 after buying an additional 2,420 shares during the last quarter. Ronna Sue Cohen boosted its stake in shares of Pfizer by 0.4% in the fourth quarter. Ronna Sue Cohen now owns 7,805 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 33 shares during the last quarter. Finally, Lincoln Capital boosted its stake in shares of Pfizer by 5.7% in the fourth quarter. Lincoln Capital now owns 8,316 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 446 shares during the last quarter.

Shares of Pfizer Inc. (NYSE:PFE) opened at 30.67 on Wednesday. The stock has a market capitalization of $189.33 billion and a price-to-earnings ratio of 23.03. Pfizer Inc. has a 12-month low of $28.47 and a 12-month high of $36.46. The stock’s 50 day moving average is $31.74 and its 200-day moving average is $33.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.09. The firm had revenue of $12.10 billion for the quarter, compared to analysts’ expectations of $11.56 billion. The firm’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.57 EPS. On average, analysts expect that Pfizer Inc. will post $2.18 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 2nd. Investors of record on Friday, February 5th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date is Wednesday, February 3rd. This is an increase from Pfizer’s previous quarterly dividend of $0.24.

Several research firms have recently weighed in on PFE. JPMorgan Chase & Co. upped their price target on shares of Pfizer from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Monday, November 2nd. Cowen and Company upped their price target on shares of Pfizer from $34.00 to $35.00 and gave the stock a “market perform” rating in a report on Monday, November 2nd. Nord/LB reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Finally, Independent Research GmbH reaffirmed a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a report on Wednesday, October 28th. Six investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.83.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.